Όλο το DSpace

Πλοήγηση ανά Θέμα "LONG-TERM TREATMENT"

Αποτελέσματα 1-3 από 3

    • Clinical trials in restless legs syndrome - Recommendations of the European RLS study group (EURLSSG) 

      Trenkwalder, C.; Kohnen, R.; Allen, R. P.; Benes, H.; Ferini-Strambi, L.; Garcia-Borreguero, D.; Hadjigeorgiou, G. M.; Happe, S.; Hogl, B.; Hornyak, M.; Klein, C.; Nass, A.; Montagna, P.; Oertel, W. H.; O'Keeffe, S.; Paulus, W.; Poewe, W.; Provini, F.; Pramstaller, P. P.; Sieminski, M.; Sonka, K.; Stiasny-Kolster, K.; de Weerd, A.; Wetter, T. C.; Winkelmann, J.; Zucconi, M. (2007)
      The European Restless Leas Syndrome (RLS) Study Group (EURLSSG) is an association of European RLS experts who are actively involved in RLS research. A major aim of the Study Group is the development and continuous improvement ...

    • Current trends in the management of uremic restless legs syndrome: A systematic review on aspects related to quality of life, cardiovascular mortality and survival 

      Sakkas, G. K.; Giannaki, C. D.; Karatzaferi, C.; Maridaki, M.; Koutedakis, Y.; Hadjigeorgiou, G. M.; Stefanidis, I. (2015)
      Restless legs syndrome (RLS) affects almost one out of three end-stage renal disease patients. This review assesses the current treatment options for uremic RLS and the potential benefits of those treatments on quality of ...

    • Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study 

      Montes, A.; Perez-Pampin, E.; Navarro-Sarabia, F.; Moreira, V.; de la Sema, A. R.; Magallares, B.; Vasilopoulos, Y.; Sarafidou, T.; Fernandez-Nebro, A.; Ordonez, M. D.; Narvaez, J.; Canete, J. D.; Marquez, A.; Pascual-Salcedo, D.; Joven, B.; Carreira, P.; Moreno-Ramos, M. J.; Caliz, R.; Ferrer, M. A.; Garcia-Portales, R.; Blanco, F. J.; Magro, C.; Raya, E.; Valor, L.; Alegre-Sancho, J. J.; Balsa, A.; Martin, J.; Plant, D.; Isaacs, J.; Morgan, A. W.; Barton, A.; Wilson, A. G.; Gomez-Reino, J. J.; Gonzalez, A.; Braggss (2015)
      Introduction: We have hypothesized that incompatibility between the G1m genotype of the patient and the G1m1 and G1m17 allotypes carried by infliximab (INX) and adalimumab (ADM) could decrease the efficacy of these anti-tumor ...